Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Metrics to compare | GALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGALTPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.7x | −3.2x | −0.5x | |
PEG Ratio | −0.31 | 0.01 | 0.00 | |
Price/Book | −1.9x | 1.9x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.3x | |
Upside (Analyst Target) | 68.1% | 191.5% | 40.1% | |
Fair Value Upside | Unlock | 0.9% | 5.1% | Unlock |